BACKGROUND AND PURPOSE: Childhood arterial ischemic stroke treatment guidelines recommend extended anticoagulation in cardioembolism and dissection. We sought to investigate the safety of extended anticoagulation in childhood arterial ischemic stroke with nonmoyamoya arteriopathy, for which the risk of recurrent stroke is high. METHODS: Thirty-seven patients with childhood-onset arterial ischemic stroke with acute arteriopathy (excluding moyamoya) were diagnosed between 1999 and 2007 and treated with anticoagulation for at least 4 weeks. Patients were followed in hospital-based cohort studies at 2 centers and systematically assessed for bleeding episodes and recurrent events. RESULTS: Over a cumulative anticoagulation duration of 1329 patient-months, there were no major bleeding episodes and 2 clinically relevant bleeding episodes. Cumulative probability of recurrent arterial ischemic stroke at 1 year was 14%. CONCLUSIONS: Anticoagulation can be used safely for secondary arterial ischemic stroke prevention in children with acute nonmoyamoya arteriopathy. Anticoagulation is worthy of evaluation in future randomized, controlled treatment trials in this disease.
BACKGROUND AND PURPOSE: Childhood arterial ischemic stroke treatment guidelines recommend extended anticoagulation in cardioembolism and dissection. We sought to investigate the safety of extended anticoagulation in childhood arterial ischemic stroke with nonmoyamoya arteriopathy, for which the risk of recurrent stroke is high. METHODS: Thirty-seven patients with childhood-onset arterial ischemic stroke with acute arteriopathy (excluding moyamoya) were diagnosed between 1999 and 2007 and treated with anticoagulation for at least 4 weeks. Patients were followed in hospital-based cohort studies at 2 centers and systematically assessed for bleeding episodes and recurrent events. RESULTS: Over a cumulative anticoagulation duration of 1329 patient-months, there were no major bleeding episodes and 2 clinically relevant bleeding episodes. Cumulative probability of recurrent arterial ischemic stroke at 1 year was 14%. CONCLUSIONS: Anticoagulation can be used safely for secondary arterial ischemic stroke prevention in children with acute nonmoyamoya arteriopathy. Anticoagulation is worthy of evaluation in future randomized, controlled treatment trials in this disease.
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: D Dix; M Andrew; V Marzinotto; K Charpentier; S Bridge; P Monagle; G deVeber; M Leaker; A K Chan; M P Massicotte Journal: J Pediatr Date: 2000-04 Impact factor: 4.406
Authors: E Steve Roach; Meredith R Golomb; Robert Adams; Jose Biller; Stephen Daniels; Gabrielle Deveber; Donna Ferriero; Blaise V Jones; Fenella J Kirkham; R Michael Scott; Edward R Smith Journal: Stroke Date: 2008-07-17 Impact factor: 7.914
Authors: Nicholas V Stence; Laura Z Fenton; Neil A Goldenberg; Jennifer Armstrong-Wells; Timothy J Bernard Journal: Curr Treat Options Neurol Date: 2011-12 Impact factor: 3.598
Authors: Michael Y Uohara; Lauren A Beslow; Lori Billinghurst; Brianna M Jones; Sudha K Kessler; Daniel J Licht; Rebecca N Ichord Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: Mubeen F Rafay; Kevin A Shapiro; Ann-Marie Surmava; Gabrielle A deVeber; Adam Kirton; Heather J Fullerton; Catherine Amlie-Lefond; Bernhard Weschke; Nomazulu Dlamini; Jessica L Carpenter; Mark T Mackay; Michael Rivkin; Alexandra Linds; Timothy J Bernard Journal: Neurology Date: 2020-05-26 Impact factor: 9.910